Market Closed -
London S.E.
11:35:20 2024-07-05 EDT
|
5-day change
|
1st Jan Change
|
8.5
GBX
|
0.00%
|
|
-2.86%
|
-87.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
18.86
|
40.97
|
62.87
|
39.22
|
66.69
|
8.141
|
-
|
Enterprise Value (EV)
1 |
11.36
|
31.23
|
58.22
|
34.32
|
60.31
|
6.59
|
8.141
|
P/E ratio
|
-4.02
x
|
-5.71
x
|
-11.8
x
|
-5.75
x
|
-11.3
x
|
-1.39
x
|
-1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
61.7
x
|
-
|
629
x
|
-
|
80.2
x
|
-
|
-
|
EV / Revenue
|
37.1
x
|
-
|
582
x
|
-
|
72.5
x
|
-
|
-
|
EV / EBITDA
|
-
|
-4.78
x
|
-9.28
x
|
-4.78
x
|
-10.1
x
|
-0.99
x
|
-
|
EV / FCF
|
-
|
-5.68
x
|
-11.4
x
|
-5.82
x
|
-11
x
|
-1.16
x
|
-
|
FCF Yield
|
-
|
-17.6%
|
-8.8%
|
-17.2%
|
-9.08%
|
-86.2%
|
-
|
Price to Book
|
-
|
3.29
x
|
8.37
x
|
5.14
x
|
7.25
x
|
2.4
x
|
-
|
Nbr of stocks (in thousands)
|
43,865
|
59,817
|
59,872
|
73,307
|
95,272
|
95,771
|
-
|
Reference price
2 |
0.4300
|
0.6850
|
1.050
|
0.5350
|
0.7000
|
0.0850
|
0.0850
|
Announcement Date
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.3059
|
-
|
0.1
|
-
|
0.8316
|
-
|
-
|
EBITDA
1 |
-
|
-6.536
|
-6.274
|
-7.178
|
-5.971
|
-6.661
|
-
|
EBIT
1 |
-5.585
|
-6.553
|
-6.287
|
-7.776
|
-6.736
|
-6.416
|
-8
|
Operating Margin
|
-1,825.62%
|
-
|
-6,286.95%
|
-
|
-810.05%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.521
|
-6.481
|
-6.271
|
-7.712
|
-6.446
|
-6.387
|
-
|
Net income
1 |
-4.708
|
-5.411
|
-5.339
|
-6.504
|
-5.657
|
-5.618
|
-8
|
Net margin
|
-1,539.02%
|
-
|
-5,339.48%
|
-
|
-680.3%
|
-
|
-
|
EPS
2 |
-0.1070
|
-0.1200
|
-0.0890
|
-0.0930
|
-0.0620
|
-0.0610
|
-0.0850
|
Free Cash Flow
1 |
-
|
-5.494
|
-5.121
|
-5.893
|
-5.475
|
-5.682
|
-
|
FCF margin
|
-
|
-
|
-5,120.69%
|
-
|
-658.44%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7.5
|
9.74
|
4.65
|
4.9
|
6.38
|
1.55
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-5.49
|
-5.12
|
-5.89
|
-5.48
|
-5.68
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-53.6%
|
-53.5%
|
-85.9%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.2100
|
0.1300
|
0.1000
|
0.1000
|
0.0400
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
0
|
0.03
|
0
|
0
|
0
|
-
|
Capex / Sales
|
6.85%
|
-
|
30.26%
|
-
|
0.1%
|
-
|
-
|
Announcement Date
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Last Close Price
0.085
GBP Average target price
1.883
GBP Spread / Average Target +2,115.68% Consensus |
1st Jan change
|
Capi.
|
---|
| -87.86% | 10.43M | | +16.61% | 122B | | +17.75% | 112B | | +17.23% | 25.91B | | -24.11% | 19.33B | | -18.56% | 16.17B | | -18.47% | 15.56B | | -47.75% | 14.65B | | +57.35% | 14.34B | | +5.62% | 14B |
Bio Therapeutic Drugs
|